Clinical Trials List
2021-09-01 - 2025-03-31
Phase I/II
Recruiting5
ICD-10C11.0
Malignant neoplasm of superior wall of nasopharynx
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9147.0
Malignant neoplasm of superior wall of nasopharynx
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Cheng-Lung Hsu Division of Hematology & Oncology
- Shu-Hang Ag Division of Hematology & Oncology
- Li-Yu Lee Division of Hematology & Oncology
- Pei-Wei Huang Division of Hematology & Oncology
- Chia-Hsun Hsieh Division of Hematology & Oncology
- Hung Chang Division of Hematology & Oncology
- Chi-Ting Liau Division of Hematology & Oncology
- 廖俊達 Division of Hematology & Oncology
- Jen-Shi Chen Division of Hematology & Oncology
- Tzu-Chen Yen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 廖斌志 Division of Hematology & Oncology
- 黃彥霖 Division of Hematology & Oncology
- HUAI-CHENG HUANG Division of Hematology & Oncology
- 陳國興 Division of Hematology & Oncology
- 張端瑩 Division of Hematology & Oncology
- YA-FANG CHEN Division of Hematology & Oncology
- RUEY-LONG HONG Division of Hematology & Oncology
- Wei-Wu Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 陳盛裕 Division of Hematology & Oncology
- Mu-Hsin Chang Division of Hematology & Oncology
- Tien-Hua Chen Division of Hematology & Oncology
- Sheng-Yu Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
170 participants
